Efficacy of Aerobika
Phase 4
- Conditions
- Chronic Obstructive Pulmonary DiseaseCOPD
- Registration Number
- JPRN-jRCT1032180010
- Lead Sponsor
- Mineshita Masamichi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Subject has post-long acting bronchodilator forced expiratory volume in first second (FEV1) is less than 80% predicted.
Subject has declared that he/she has stopped smoking for at least 8 weeks prior to entering the study.
Subject has respiratory symptoms 10 and over on the CAT total score, and has the phlegm symptoms 2 and over on the CAT phlegm score.
Subject has read, understood, and signed the informed consent form.
Exclusion Criteria
The condition that the investigator judges to exclude from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in FEV1 before and after 4-week treatment with Aerobika.
- Secondary Outcome Measures
Name Time Method Following parameters will be assessed for before and at 4-week treatment with Aerobika.<br>1. VC, FVC, V50, and V25<br>2. IOS (R5, R5ins, R5exp, R20, X5, X5ins, X5exp, Fres, Ax)<br>3. 6 minute-walking test<br>4. CAT score, mMRC<br>5. Acute exacerbation